Pfizer to Acquire Array BioPharma What is Array BioPharma Inc.'s industry? Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Array BioPharma Inc. is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. —Proposed acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term —Opportunity to strengthen category leadership in Oncology with the addition of a breakthrough combination of BRAF/MEK inhibitors under investigation for a potential first-in-class therapy for patients with BRAF-mutant metastatic colorectal cancer —Expands Pfizer’s pipeline with multiple high-potential targeted investigational cancer therapies and adds a large portfolio of royalty-generating out-licensed medicines —Plans to maintain highly productive research unit in Boulder to complement Pfizer’s research hubs —Transaction valued at $48 per Array share in cash, for a total enterprise value of approximately $11.4 billionArray’s portfolio includes the approved combined use of BRAFTOVIIn the U.S., colorectal cancer is the third most common type of cancer in men and women. Access all contacts Where are Array BioPharma Inc.'s headquarters?
“Pfizer shares our commitment to patients and a passion for advancing science to develop even more options for individuals with unmet needs. This information—including product information—is intended only for residents of the United States. At the time the tender offer is commenced, Pfizer and its acquisition subsidiary will file a tender offer statement on Schedule TO and thereafter Array will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. Pfizer accepts no responsibility for the content of linked sites. Array BioPharma has 298 employees across 9 locations and $173.77 M in annual revenue in FY 2018. a*****@arraybiopharma.com You may read and copy any reports or other information filed by Pfizer or Array at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Saleslift Technologies Private Limited
b*****@arraybiopharma.com
+1******00 Tony Piscopio, Kevin Koch, David Snitman, and K.C. The solicitation and offer to buy Array stock will only be made pursuant to an Offer to Purchase and related tender offer materials. For more than 150 years, we have worked to make a difference for all who rely on us.
Array BioPharma Inc.'s official website is http://www.arraybiopharma.com How many employees are working at Array BioPharma Inc.? +1******00 The staff at Array BioPharma come from unusually diverse demographic backgrounds. Shares of Array BioPharma Inc. arry rocketed 56% toward a record high in premarket trading Monday, after biopharmaceutical company developing …
d*****@arraybiopharma.com What is Array BioPharma Inc.'s revenue?
Array BioPharma Inc. has
The 10 Best Stocks for 2019 — So Far.
An estimated 140,250 patients were diagnosed with cancer of the colon or rectum in 2018, and approximately 50,000 are estimated to die of their disease each year.“Today’s announcement reinforces our commitment to deploy our capital to bring breakthroughs that change patients’ lives while creating shareholder value,” said Albert Bourla, chief executive officer of Pfizer. OUR MEDICINES IN DEVELOPMENT Our priority is researching and developing medicines and vaccines that will benefit patients around the world. Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its virtual Investor Day held over two days: Monday, September 14, 2020 from 1:00 p.m. EDT to 4:00 p.m. EDT and Tuesday, September 15, 2020 from 10:00 a.m. EDT to 1:00 p.m. EDT.